| 乙型肝炎肝硬化抗病毒治疗安全性与疗效观察 |
| |
| 引用本文： | 李冰,李梵,纪冬,张健,邵清,韩萍,李永纲,陈国凤,王慧芬,陈菊梅.乙型肝炎肝硬化抗病毒治疗安全性与疗效观察[J].肝脏,2010,15(1):8-10. |
| |
| 作者姓名： | 李冰 李梵 纪冬 张健 邵清 韩萍 李永纲 陈国凤 王慧芬 陈菊梅 |
| |
| 作者单位： | 解放军第三○二医院,北京,100039 |
| |
| 基金项目： | 军队"十一五"中医药研发推广专项重大临床攻关课题 |
| |
| 摘 要： | 目的观察恩替卡韦等核苷类似物在乙型肝炎肝硬化失代偿期患者中抗病毒治疗的安全性与疗效。方法69例乙型肝炎肝硬化失代偿期患者随机分成2组,分别给予恩替卡韦、拉米夫定联合阿德福韦酯两种方案,观察所有病例症状、体征、生化学指标、HBV DNA阴转、HBeAg阴转、抗-HBe阳转以及Child-Pugh评分分级变化等情况。结果两组患者无一例死亡,临床症状、体征、肝功能均有明显改善,HBeAg血清转换率分别为42.1%、41.9%,差异无统计学意义(P0.05),HBV DNA阴转率两组分别为92.1%、84.1%,组间比较差异无统计学意义(P0.05)。结论乙型肝炎肝硬化失代偿期患者选用恩替卡韦或拉米夫定联合阿德福韦酯安全性及疗效无显著差异。
|
| 关 键 词： | 肝硬化 失代偿 抗病毒治疗 |
Clinical observation on 69 cases of decompensated cirrhosis patients following chronic hepatitis B virus infection treated with entecavir and other nucleoside drugs |
| |
| LI Bing,LI Fan,JI Dong,ZHANG Jian,SHAO Qing,HAN Pan,LI Yong-gang,CHEN Guo-feng,WANG Hui-fen,CHEN Ju-mei.Clinical observation on 69 cases of decompensated cirrhosis patients following chronic hepatitis B virus infection treated with entecavir and other nucleoside drugs[J].Chinese Hepatology,2010,15(1):8-10. |
| |
| Authors: | LI Bing LI Fan JI Dong ZHANG Jian SHAO Qing HAN Pan LI Yong-gang CHEN Guo-feng WANG Hui-fen CHEN Ju-mei |
| |
| Institution: | LI Bing,LI Fan,JI Dong,ZHANG Jian,SHAO Qing,HAN Pan,LI Yong-gang,CHEN Guo-feng,WANG Hui-fen,CHEN Ju-mei.The 302 Hospital of PLA,Beijing 100039,China |
| |
| Abstract: | Objective To determine the clinical therapeutic effect and security of entecavir and other nucleoside drugs on decompensated cirrhosis patients following chronic hepatitis.Methods Sixty-nine cases of hepatitis B patients with cirrhosis were randomly divided into 2 groups.Patients in group A and B were treated with entecavir and combination of lamivudine with adefovir for 48 weeks,respectively.Clncal manifestations,biochemical indicators,Child-Pugh classification,HBV DNA loads,HBeAg and anti-HBe situations w... |
| |
| Keywords: | Cirrhosis Decompensation Anti-virus treatment |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
